Oryzon Genomics Archives

Born2Invest uses cookies in order to improve your experience and make further customizations to how we present our content. By continuing to use our website, you accept and give your consent to our practices as described in the following: our revised Privacy Policy, Cookie Policy, and Terms of Use.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Born2Invest

All posts tagged "Oryzon Genomics"

Oryzon up 3% After Progress in Trial of Its Drug for Personality Disorder

Oryzon Genomics Rises 3% After Progress in a Clinical Study of Leukemia

Oryzon Genomics Increases its Half-Year Losses by 83%, to Over 1 Million Euros

Oryzon Requests the Start of Trading of 378,918 New Shares after Increasing its Capital

Oryzon and Reig Jofre Both Selected to Participate in the Med4Cure Project

Oryzon Cuts Losses by 20.7%, Faes Farma Earns almost 92 Million in 2023

Oryzon Lost €1.6 Million in the First Quarter of 2023